HPV Cervical Pathology Management

Cytologic Classification

The American College of Obstetricians and Gynecologists recommends classifying HPV-related cervical pathology into cytologic grades, with cytology ranging from ASC-US to HSIL, each requiring distinct management based on disease risk and patient age 1
The Bethesda System reports cervical cytology abnormalities, progressing from lowest to highest cancer risk, with ASC-US being the most common abnormality, occurring in approximately 4% of cytologic smears, with a 9.7% risk of CIN 2 or worse 2, 3

The American Society for Colposcopy and Cervical Pathology recommends histologic grades representing the actual tissue diagnosis obtained through colposcopy-directed biopsy, with CIN 1, CIN 2, and CIN 3 requiring distinct management based on disease risk and patient age 1
CIN 1 has mild dysplasia with high spontaneous regression rates (>90% within 24 months), managed conservatively in most cases, while CIN 2 has moderate dysplasia, considered the treatment threshold in the United States, though approximately 40% regress over 6 months 4, 5, 6

The American College of Obstetricians and Gynecologists recommends reflex HPV DNA testing as the preferred triage option for adult women with ASC-US, with immediate colposcopy if HPV positive, and repeat HPV testing or cotesting in 12 months if HPV negative 1, 3
Immediate colposcopy is recommended for all adult women with LSIL cytology, as HPV testing does not provide useful triage (80-86% are HR-HPV positive), with post-colposcopy with CIN 1 or negative biopsy requiring conservative follow-up with repeat cytology every 6-12 months or HPV testing at 12 months 4, 8

The American Academy of Pediatrics recommends conservative management for adolescents with any cytologic or histologic diagnosis except CIN 3 and adenocarcinoma in situ, with no screening before age 21 regardless of sexual history 1, 3, 5, 6
The American College of Obstetricians and Gynecologists recommends cotesting (cytology plus HPV testing) every 5 years for women aged 30-65 years, with a single negative HPV test carrying negligible risk for CIN 3, and screening may cease at age 65 with adequate prior screening and normal results 1, 2

The American Society for Colposcopy and Cervical Pathology recommends never using HPV testing alone to triage LSIL, as 80-86% are HPV positive, making it non-discriminatory, and never delaying colposcopy for high-grade abnormalities (HSIL, ASC-H) based on negative HPV results, as these require colposcopy regardless of HPV status 4, 7